About NicOx

Profile
Pipeline

Products
Naproxcinod
NCX 6560
Full portfolio
Maximizing portfolio
Co-development
Research alliances
Technology
People
Board of Directors
Management Team
Contacts
Careers
Investor & media
Press releases
Investor relations

Fact file
Financials
Corporate governance

Conferences
Home
Directions to NicOx
Site en français


NicOx fact file
Listing Segment:

Euronext Paris
: Eurolist Next Economy
FTSE Classification Economical group: non cyclical consumer goods (40)
Industrial sector: pharmaceuticals (48)
Industry sub-sector: pharmaceuticals (480)
Euroclear France code: 7413
Reuters code: NCOX.PA
Bloomberg code: COX.FP
IPO date: November 3, 1999
Gross proceeds: 33 million euros
Follow-on offering: May 21, 2001
Gross proceeds: 59 million euros
Private placement: September 30, 2004
Gross proceeds: 26 million euros
Private placement: April 28, 2006
Gross proceeds: approx. 45.5 million euros
Rights issue : February 16, 2007
Net Proceeds : 120.7 million euros
Share price: Euronext
Share capital : € 9,435,911.80
Number of outstanding shares: 47,179,559
Number of voting rights
as of January 31, 2008:
47,265,911
Total number of voting right
calculated on the basis of all
the shares to which voting right
are attached even if exercise
thereof is suspended:
47,179,559
Public (as of 05.03.07): 97.13%
Analyst coverage : Search based in France / UK
Shareholder structure:

To its knowledge, as of 5 March, 2007, NicOx' capital structure was:
Public:
Main shareholders:

97.13%
Oppenheimer Funds
QVT Fund LLP
AQR Capital Management
Pfizer Overseas Pharmaceuticals
Baker Brothers Investments
HealthCap Group

Founding managers: 2.87%

Contact:

Karl HANKS
Director of investor relations and Corporate Communications
hanks@nicox.com